In the 1990s, New York spent over a billion dollars to battle an outbreak of tuberculosis, and now with almost one in ten doses of common anti-TB drugs failing to meet basic standards, there is growing concern that resistance may be making past treatments obsolete. Two key anti-TB drugs, isoniazid and rifampicin, originally developed by Roche, have been shown in a study published this week in the International Journal of more »
Some researchers estimate that roughly 90% of all bacteria found in or on human beings cannot be cultured. Treponema pallidum, better known as syphilis, represents a prime example. Currently, the only way to grow syphilis is by inoculating a living animal, such as a hamster. Rest assured, few hospitals have the resources to routinely diagnose a patient with syphilis, or any other disease, using lab animals. Currently, diagnosing syphilis relies more »
Ahh, the excitement of Biotech Investing! Buy a company that is currently in clinical trials, wait for the data to be released, and then watch your investment go through the roof, right?
Biotech will break your heart more often than not
Myriad Genetics (NASDAQ: MYGN) offers an interesting investment proposition. On the one hand it is a fast growing and highly cash generative company with strong future prospects. On the other, it is a company which is fraught with legal challenges to its patents and whose growth prospects are largely dependent on the reimbursement agenda of the managed care industry. Sometimes the hardest part in investing is quantifying risk and it more »
George S. Mack, The Life Sciences Report
Think beyond cancer for big gains in biotech.
I'm not alone in thinking that cancers have assumed more than their share of interest from investors. In fact, sometimes it feels like oncology is all biotech and pharma care about. Blood-related cancers and solid tumors account for 13% of deaths worldwide, but a disproportionate 70% of investment dollars flow to oncology research. This more »